(Q24234046)

5

0 references

Andrea Cipriani

4

0 references

Rachel Churchill

6

0 references

Toshi A Furukawa

7

Toshi A Furukawa

0 references

Atsuo Nakagawa

3

Atsuo Nakagawa

0 references

Ichiro M Omori

2

Ichiro M Omori

0 references

Norio Watanabe

1

Cochrane Database of Systematic Reviews

Norio Watanabe

0 references

language of work or name

English

0 references

publication date

2011

0 references

published in

0 references

issue

12

0 references

page(s)

CD006528

0 references

cites work

Paroxetine versus other anti-depressive agents for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Venlafaxine versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Citalopram versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Fluvoxamine versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Milnacipran versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Escitalopram versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Fluoxetine versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A rating scale for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Sertraline versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Amitriptyline versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Imputing missing standard deviations in meta-analyses can provide accurate results

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A New Depression Scale Designed to be Sensitive to Change

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

FKBP5 polymorphisms and antidepressant response in geriatric depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Evaluation of networks of randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Are we going to increase the use of antidepressants up to that of benzodiazepines?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Australian and New Zealand clinical practice guidelines for the treatment of depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Industry sponsorship and authorship of clinical trials over 20 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

27 September 2017

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparative responsiveness of generic and specific quality-of-life instruments

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Prevalence of sexual dysfunction among newer antidepressants.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Standardizing the Hamilton Depression Rating Scale: past, present, and future

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A review of the pharmacological and clinical profile of mirtazapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Does mirtazapine have a more rapid onset than SSRIs?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Depressed in-patients respond differently to imipramine and mirtazapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

The pharmacologic profile of mirtazapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A consumer's guide to subgroup analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770).

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine is more effective than trazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Treatment of mood-congruent psychotic depression with imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Trait anxiety and the effect of a single high dose of diazepam in unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

A Review of the Pharmacological and Clinical Profile of Mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Reboxetine versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Sertraline versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Association between unreported outcomes and effect size estimates in Cochrane meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Amitriptyline for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Indirect comparisons: the mesh and mess of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006528.PUB2

The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4158430

A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients

29 November 2018

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

STAR*D: what have we learned?

1 reference

12 December 2020

A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression

1 reference

12 December 2020

Mirtazapine compared with paroxetine in major depression

1 reference

12 December 2020

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

1 reference

12 December 2020

Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder

1 reference

12 December 2020

Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Issues in the use of change scores in randomized trials

1 reference

12 December 2020

A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression

1 reference

12 December 2020

A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression

1 reference

12 December 2020

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

1 reference

12 December 2020

10.1002/14651858.CD006528.PUB2

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

22161405

1 reference